These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 33377563)

  • 21. Phenotypic/Genotypic Profile of Children with Neuronal Ceroid Lipofuscinosis in Southern Brazil.
    Santos BV; de Souza J; Zeny MS; Santos MLSF; do Valle DA
    Neuropediatrics; 2024 Oct; 55(5):303-310. PubMed ID: 38857616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuronal ceroid lipofuscinosis type 2: an Australian case series.
    Johnson AM; Mandelstam S; Andrews I; Boysen K; Yaplito-Lee J; Fietz M; Nagarajan L; Rodriguez-Casero V; Ryan MM; Smith N; Scheffer IE; Ellaway C
    J Paediatr Child Health; 2020 Aug; 56(8):1210-1218. PubMed ID: 32329550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravitreal gene therapy preserves retinal function in a canine model of CLN2 neuronal ceroid lipofuscinosis.
    Kick GR; Whiting REH; Ota-Kuroki J; Castaner LJ; Morgan-Jack B; Sabol JC; Meiman EJ; Ortiz F; Katz ML
    Exp Eye Res; 2023 Jan; 226():109344. PubMed ID: 36509165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis.
    Vuillemenot BR; Kennedy D; Cooper JD; Wong AM; Sri S; Doeleman T; Katz ML; Coates JR; Johnson GC; Reed RP; Adams EL; Butt MT; Musson DG; Henshaw J; Keve S; Cahayag R; Tsuruda LS; O'Neill CA
    Mol Genet Metab; 2015 Feb; 114(2):281-93. PubMed ID: 25257657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generation of pathogenic TPP1 mutations in human stem cells as a model for neuronal ceroid lipofuscinosis type 2 disease.
    Ma L; Prada AM; Schmidt M; Morrow EM
    Stem Cell Res; 2021 May; 53():102323. PubMed ID: 33845243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted re-sequencing for early diagnosis of genetic causes of childhood epilepsy: the Italian experience from the 'beyond epilepsy' project.
    Amadori E; Scala M; Cereda GS; Vari MS; Marchese F; Di Pisa V; Mancardi MM; Giacomini T; Siri L; Vercellino F; Serino D; Orsini A; Bonuccelli A; Bagnasco I; Papa A; Minetti C; Cordelli DM; Striano P
    Ital J Pediatr; 2020 Jul; 46(1):92. PubMed ID: 32631363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Late infantile neuronal ceroid lipofuscinosis: a new mutation in Arabs.
    Goldberg-Stern H; Halevi A; Marom D; Straussberg R; Mimouni-Bloch A
    Pediatr Neurol; 2009 Oct; 41(4):297-300. PubMed ID: 19748052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CLN2 Disease (Classic Late Infantile Neuronal Ceroid Lipofuscinosis).
    Kohlschütter A; Schulz A
    Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():682-8. PubMed ID: 27491216
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cerliponase alfa changes the natural history of children with neuronal ceroid lipofuscinosis type 2: The first French cohort.
    Estublier B; Cano A; Hoebeke C; Pichard S; Scavarda D; Desguerre I; Auvin S; Chabrol B
    Eur J Paediatr Neurol; 2021 Jan; 30():17-21. PubMed ID: 33348105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protracted late infantile ceroid lipofuscinosis due to TPP1 mutations: Clinical, molecular and biochemical characterization in three sibs.
    Di Giacopo R; Cianetti L; Caputo V; La Torraca I; Piemonte F; Ciolfi A; Petrucci S; Carta C; Mariotti P; Leuzzi V; Valente EM; D'Amico A; Bentivoglio A; Bertini E; Tartaglia M; Zampino G
    J Neurol Sci; 2015 Sep; 356(1-2):65-71. PubMed ID: 26143525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel CLN2/TPP1 mutation in a patient with late infantile neuronal ceroid lipofuscinosis.
    Yu F; Liu XM; Chen YH; Zhang SQ; Wang K
    Neurol Sci; 2015 Oct; 36(10):1917-9. PubMed ID: 26032578
    [No Abstract]   [Full Text] [Related]  

  • 32. Ongoing retinal degeneration despite intraventricular enzyme replacement therapy with cerliponase alfa in late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2 disease).
    Dulz S; Schwering C; Wildner J; Spartalis C; Schuettauf F; Bartsch U; Wibbeler E; Nickel M; Spitzer MS; Atiskova Y; Schulz A
    Br J Ophthalmol; 2023 Oct; 107(10):1478-1483. PubMed ID: 35772852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Tripeptidyl peptidase 1 in patients with late infantile neuronal ceroid lipofuscinosis].
    Contreras LM; Luengo WD; Zerpa N; Hernández JC; Chávez CJ; Ferrer SG
    An Pediatr (Barc); 2012 Mar; 76(3):148-52. PubMed ID: 22100780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and Molecular Characteristics of Neuronal Ceroid Lipofuscinosis in Saudi Arabia.
    Saleh MM; Hamhom AM; Al-Otaibi A; AlGhamdi M; Housawi Y; Aljadhai YI; Alameer S; Almannai M; Jad LA; Alwadei AH; Tabassum S; Alsaman A; AlAsmari A; Al Mutairi F; Althiyab H; Bashiri FA; AlHumaidi S; Alfadhel M; Mink JW; AlHashim A; Faqeih EA;
    Pediatr Neurol; 2024 Jun; 155():149-155. PubMed ID: 38653183
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Untargeted Metabolite Profiling of Cerebrospinal Fluid Uncovers Biomarkers for Severity of Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2, Batten Disease).
    Sindelar M; Dyke JP; Deeb RS; Sondhi D; Kaminsky SM; Kosofsky BE; Ballon DJ; Crystal RG; Gross SS
    Sci Rep; 2018 Oct; 8(1):15229. PubMed ID: 30323181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolution of the retinal function by flash-ERG in one child suffering from neuronal ceroid lipofuscinosis CLN2 treated with cerliponase alpha: case report.
    Rigaudière F; Nasser H; Pichard-Oumlil S; Delouvrier E; Lopez-Hernandez E; Milani P; Auvin S; Delanoë C
    Doc Ophthalmol; 2021 Aug; 143(1):99-106. PubMed ID: 33956290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Late-infantile neuronal ceroid lipofuscinosis (CLN2/Jansky-Bielschowsky type) in Oman.
    Koul R; Al-Futaisi A; Ganesh A; Rangnath Bushnarmuth S
    J Child Neurol; 2007 May; 22(5):555-9. PubMed ID: 17690061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravitreal enzyme replacement preserves retinal structure and function in canine CLN2 neuronal ceroid lipofuscinosis.
    Whiting REH; Pearce JW; Vansteenkiste DP; Bibi K; Lim S; Robinson Kick G; Castaner LJ; Sinclair J; Chandra S; Nguyen A; O'Neill CA; Katz ML
    Exp Eye Res; 2020 Aug; 197():108130. PubMed ID: 32622066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validity of a rapid and simple fluorometric tripeptidyl peptidase 1 (TPP1) assay using dried blood specimens to diagnose CLN2 disease.
    Lukacs Z; Nickel M; Murko S; Nieves Cobos P; Schulz A; Santer R; Kohlschütter A
    Clin Chim Acta; 2019 May; 492():69-71. PubMed ID: 30771299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of a
    Baranzehi T; Kordi-Tamandani DM; Najafi M; Khajeh A; Schmidts M
    J Clin Med; 2022 Oct; 11(21):. PubMed ID: 36362641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.